KLRS — Kalaris Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Allovir Announces Positive Final Results From Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Of Posoleucel In Kidney Transplant Recipients With Bk Viremia
Allovir Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Allovir Announces To Complete Enrollment In Three Phase 3 Posoleucel Studies
Brief: Allovir Announces Positive Final Results In Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation
U.S. RESEARCH ROUNDUP-Linkbancorp, Oyster Point Pharma, Viatris
U.S. RESEARCH ROUNDUP-Linkbancorp, Oyster Point Pharma, Viatris
Allovir Inc reports results for the quarter ended in September - Earnings Summary
Brief: Allovir Reports Third Quarter 2022 Financial Results
Allovir Inc expected to post a loss of 53 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Avalara, Global Blood Therapeutics, Tyson Foods
Brief: Gilead Sciences Inc reports 14.8% passive stake in Allovir
Brief: AlloVir Reports Second Quarter 2022 Financial Results
Brief: Allovir Announces $126.6 Mln Registered Direct Offering
Brief: Allovir Reports Blinded Preliminary Phase 2 Data Supporting The Ongoing Study Of Posoleucel
Brief: Allovir Reports First Quarter 2022 Financial Results
Allovir Inc expected to post a loss of 80 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-OpGen Inc, Anthem Inc, Dow Inc
U.S. STOCKS ON THE MOVE-Procter & Gamble, AlloVir, Netflix
AlloVir soars after FDA grants designation to its therapy